mTHPC pharmacokinetics following topical administration

被引:3
作者
Johansson, Ann [1 ]
Svensson, Jenny [1 ]
Andersson-Engels, Stefan [1 ]
Bendsoe, Niels [1 ]
Svanberg, Katarina [1 ]
Bigio, Irving [1 ]
Alexandratou, Eleni [1 ]
Kyriazi, Maria [1 ]
Yova, Dido [1 ]
Graefe, Susanna [1 ]
Trebst, Tilmann [1 ]
机构
[1] Lund Inst Technol, Dept Phys, SE-22100 Lund, Sweden
来源
Optical Diagnostics and Sensing VI | 2006年 / 6094卷
关键词
mTHPC; pharmacokinetics; fluorescence spectroscopy; absorption spectroscopy; fluorescence imaging; photodynamic therapy;
D O I
10.1117/12.647602
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
Measurements of concentration of sensitizers for photodynamic therapy can provide important information in the dosimetry planning and can also give input to the optimal time for treatment. There has been skepticism towards fluorescence techniques for this purpose, as the signal depends on the fluorescence yield and optical properties of the tissue. Absorption based techniques, lack on the other hand, often the sensitivity required for many sensitizers with relative weak absorption in a wavelength region where hemoglobin absorption is dominant. A direct comparison between absorption and fluorescence techniques for measuring mTHPC concentration after topical application on hairless SKH-1 mice bearing skin carcinomas has been performed. 20 mu l/cm(2) of m-THPC thermogel (0.5 mg m-THPC/ml) were applied on normal and tumor area and the concentration of mTHPC was measured at 4 and 6 hours after drug application by two methods: 1. A fluorescence imaging system capturing images at two wavelengths (500 and 650 nm) following 405 nm excitation. Signals from different regions of interest were averaged and the intensity ratio at 650 to 500 was calculated. 2. A diffuse reflectance spectroscopy system with a fiber separation of 2 mm, providing the absorbance at 652 nm. Both systems provided consistent results related to the photosensitizer concentration. The methods show a remarkable difference in the concentration of photosensitizer in normal skin and tumor. No significant difference in mTHPC concentration in tumor could be observed between the 4 and 6h groups after drug application.
引用
收藏
页码:C940 / C940
页数:8
相关论文
共 18 条
  • [1] Physical and chemical studies related to the development of m-THPC (FOSCAN®) for the photodynamic therapy (PDT) of tumours
    Bonnett, R
    Djelal, BD
    Nguyen, A
    [J]. JOURNAL OF PORPHYRINS AND PHTHALOCYANINES, 2001, 5 (08) : 652 - 661
  • [2] Coutier S, 2002, RADIAT RES, V158, P339, DOI 10.1667/0033-7587(2002)158[0339:EOIFRO]2.0.CO
  • [3] 2
  • [4] Photodynamic therapy
    Dougherty, TJ
    Gomer, CJ
    Henderson, BW
    Jori, G
    Kessel, D
    Korbelik, M
    Moan, J
    Peng, Q
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (12): : 889 - 905
  • [5] Dysart JS, 2002, PHOTOCHEM PHOTOBIOL, V75, P289, DOI 10.1562/0031-8655(2002)075<0289:RBMFPA>2.0.CO
  • [6] 2
  • [7] ENDOGENOUS PROTOPORPHYRIN-IX, A CLINICALLY USEFUL PHOTOSENSITIZER FOR PHOTODYNAMIC THERAPY
    KENNEDY, JC
    POTTIER, RH
    [J]. JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY B-BIOLOGY, 1992, 14 (04) : 275 - 292
  • [8] Kübler AC, 1999, LASER SURG MED, V25, P60, DOI 10.1002/(SICI)1096-9101(1999)25:1<60::AID-LSM8>3.0.CO
  • [9] 2-X
  • [10] Photophysical parameters, photosensitizer retention and tissue optical properties completely account for the higher photodynamic efficacy of meso-tetra-hydroxyphenyl-chlorin vs Photofrin
    Mitra, S
    Foster, TH
    [J]. PHOTOCHEMISTRY AND PHOTOBIOLOGY, 2005, 81 (04) : 849 - 859